论文部分内容阅读
目的：研究硫代硫酸钠（ＳＴＳ）是否能在体内、外作为化疗药的辅药。方法：应用ＭＴＴ法研究ＳＴＳ分别与ＡＤＭ、ＭＭＣ和ＣＤＤＰ等６种抗癌单药合用时对ＢＥＬ－７４０２和ＭＧｃ８０－３细胞的细胞毒性作用；应用小鼠肝癌腹水瘤（Ｈ２２）模型判断ＳＴＳ与ＡＤＭ等３种药合用时的抗癌疗效；２０例人原发性肝癌病人肝动脉插管化疗（ＡＤＭ、ＭＭＣ和ＣＤＤＰ）前３０ｍｉｎ静脉推注ＳＴＳ（１２５～２５ｇ／ｍ２）考察ＳＴＳ作为化疗药辅药的作用。结果：除了ＣＤＤＰ以外，ＳＴＳ（５００μｇ／ｍｌ）与ＡＤＭ等５种抗癌单药合用时对抗癌药的抗肿瘤细胞活性无明显影响（Ｐ＞００５）。当不同剂量ＳＴＳ（３５０ｍｇ／ｋｇ、３５ｍｇ／ｋｇ）分别与ＡＤＭ（６ｍｇ／ｋｇ）、ＭＭＣ（１４ｍｇ／ｋｇ）和ＣＤＤＰ（４５ｍｇ／ｋｇ）合用或仅这３种化疗药合用时，这３组腹水瘤小鼠的存活期比对照组者显著延长（Ｐ＜０００１），但３组之间无明显区别（Ｐ＞００５）。人肝癌肝动脉插管化疗时，ＳＴＳ与ＡＤＭ、ＭＭＣ和ＣＤＤＰ抗癌药合用，肝癌治疗总有效率达６０％，且可减少７０％病人的恶心、呕吐等副作用。结论：在体内，低浓度的ＳＴＳ（１２５～２５ｇ／ｍ２）可与ＡＤＭ，ＭＭ?
OBJECTIVE: To investigate whether sodium thiosulfate (STS) can be used as an adjuvant for chemotherapy drugs both in vitro and in vivo. Methods: MTT assay was used to study the cytotoxicity of STS combined with 6 kinds of anti-cancer drugs such as ADM, MMC and CDDP on BEL-7402 and MGc80-3 cells, respectively. The HCC model of mouse hepatocellular carcinoma ADM and other three kinds of drugs combined anticancer efficacy; 20 cases of primary liver cancer patients before hepatic artery catheterization chemotherapy (ADM, MMC and CDDP) intravenous injection of STS (1 25 ~ 2 5g / m2) STS as a chemotherapy drug adjuvant role. Results: In addition to CDDP, STS (500μg / ml) and ADM and other five kinds of anti-cancer drugs combined anti-cancer drug anti-tumor cell activity had no significant effect (P> 005). When different doses of STS (350 mg / kg, 35 mg / kg) were combined with ADM (6 mg / kg), MMC (1.4 mg / kg) and CDDP (45 mg / kg) or only 3 chemotherapeutic agents Group ascites tumor survival than the control group were significantly longer (P <0 .001), but no significant difference between the three groups (P> 0 05). STH combined with ADM, MMC and CDDP anticancer drugs can effectively reduce the incidence of nausea, vomiting and other side effects in 70% of patients with liver cancer. Conclusion: In vivo, low concentrations of STS (1 25 ~ 2 5g / m2) with ADM, MM?